Cyra E Leurs
Overview
Explore the profile of Cyra E Leurs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
In t Veld S, Arkani M, Post E, Antunes-Ferreira M, DAmbrosi S, Vessies D, et al.
Cancer Cell
. 2022 Sep;
40(9):999-1009.e6.
PMID: 36055228
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for...
2.
Bridel C, Leurs C, van Lierop Z, van Kempen Z, Dekker I, Twaalfhoven H, et al.
Neurology
. 2021 Sep;
97(19):e1898-e1905.
PMID: 34504023
Background And Objectives: To investigate the potential of serum neurofilament light (NfL) to reflect or predict progression mostly independent of acute inflammatory disease activity in patients with relapsing-remitting multiple sclerosis...
3.
Sestito C, Leurs C, Steenwijk M, Breve J, Twisk J, Wilhelmus M, et al.
Neurol Neuroimmunol Neuroinflamm
. 2021 Apr;
8(4).
PMID: 33906937
Objective: The clinical course of multiple sclerosis (MS) is variable and largely unpredictable pointing to an urgent need for markers to monitor disease activity and progression. Recent evidence revealed that...
4.
van Lierop Z, Wieske L, Koel-Simmelink M, Chatterjee M, Dekker I, Leurs C, et al.
Mult Scler
. 2021 Apr;
28(1):102-110.
PMID: 33890520
Background: Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS). Objective: To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing-remitting...
5.
Tijhuis F, Broeders T, Santos F, Schoonheim M, Killestein J, Leurs C, et al.
Neuroimage Clin
. 2021 Jan;
29:102556.
PMID: 33472144
Background: More than 80% of multiple sclerosis (MS) patients experience symptoms of fatigue. MS-related fatigue is only partly explained by structural (lesions and atrophy) and functional (brain activation and conventional...
6.
Sol N, Leurs C, Veld S, Strijbis E, Vancura A, Schweiger M, et al.
Mult Scler J Exp Transl Clin
. 2020 Aug;
6(3):2055217320946784.
PMID: 32843989
Background: In multiple sclerosis (MS), clinical assessment, MRI and cerebrospinal fluid are important in the diagnostic process. However, no blood biomarker has been confirmed as a useful tool in the...
7.
Bridel C, Eijlers A, van Wieringen W, Koel-Simmelink M, Leurs C, Schoonheim M, et al.
Front Mol Neurosci
. 2018 Nov;
11:371.
PMID: 30429773
The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. We investigated the predictive value of the plasma proteome at...
8.
Eshaghi A, Marinescu R, Young A, Firth N, Prados F, Cardoso M, et al.
Brain
. 2018 May;
141(6):1665-1677.
PMID: 29741648
See Stankoff and Louapre (doi:10.1093/brain/awy114) for a scientific commentary on this article.Grey matter atrophy is present from the earliest stages of multiple sclerosis, but its temporal ordering is poorly understood....
9.
Kleerekooper I, van Kempen Z, Leurs C, Dekker I, Rispens T, Lissenberg-Witte B, et al.
Neurol Neuroimmunol Neuroinflamm
. 2018 Jan;
5(1):e424.
PMID: 29379823
Objective: To investigate disease activity and disability progression following pregnancy-related discontinuation of natalizumab (NTZ) in patients with relapsing-remitting MS. Methods: A retrospective cohort study of clinical and radiologic data in...
10.
Eshaghi A, Prados F, Brownlee W, Altmann D, Tur C, Cardoso M, et al.
Ann Neurol
. 2018 Jan;
83(2):210-222.
PMID: 29331092
Objective: Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation...